AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say

Addressing an investor meeting, CFO Bill Chase said Humira should continue strong growth through 2022, while helping leverage the launch and ramp up of successors like risankizumab and upadacitinib.

Businessman draws a statistical trend line

For AbbVie Inc., Humira (adalimumab) is always the elephant in the room – and it has been since the firm's spinout from Abbott Laboratories Inc. in 2013. As the company pumps up investor expectations for late-stage candidates to expand its immunology portfolio and leverage Humira, a pair of executives reviewed the strategic choices AbbVie has made since its inception.

Chief Financial Officer Bill Chase and Scott Brun, divisional VP of infectious diseases and immunology development, detailed this strategy during...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.